Marker Therapeutics gains on EMA's 'orphan drug' tag for blood cancer therapy

Marker Therapeutics

10/07/2023 17:12

(Updates)
    ** Shares of cancer immunotherapy developer Marker
Therapeutics Inc  MRKR.O  rise 19.82% to $5.2
    ** Company says European Medicines Agency (EMA) granted
"orphan drug" designation to its experimental therapy, MT-401,
to treat patients with acute myeloid leukemia (AML)
    ** AML is a type of cancer in which the bone marrow makes a
large number of abnormal blood cells
    ** EMA's orphan designation is assigned to a medicine
intended for use against a life-threatening or chronically
debilitating condition that affect fewer than five in 10,000
persons in the European Union
    ** Co in September received a $2 mln grant from U.S. FDA for
MT-401's mid-stage trial in treating patients with AML following
a type of stem cell transplant
    ** MT-401 already has the U.S. health regulator's "orphan
drug" tag to treat patients with post-transplant AML 
    ** Including session's gain, stock up 95.6% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))